{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:01:59Z","timestamp":1790758919402,"version":"4.1.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been in use for 20 years. There have been concerns about their safety in patients with neuroendocrine neoplasms (NENs). The reports of GLP-1 receptor (GLP-1R)-driven proliferation of C-cell neoplasms in rodent studies had led to the black-box warning against their use in patients with medullary thyroid carcinoma or multiple endocrine neoplasia type 2. In this review, we have attempted to evaluate the physiological and pathological expression of GLP-1Rs in various endocrine organs and summarize the preclinical and clinical evidence regarding the effect of GLP-1RA exposure and risk of NENs. Glucagon-like peptide-1 receptor expression has not only been found in non-neoplastic tissues such as neurohypophysis, duodenal glands and pancreatic islets, but also in neuroendocrine tumors (NETs). Preclinical studies have demonstrated the proliferative effects of GLP-1RA in cell lines representing pancreatic NETs and small intestinal NETs. The available data from retrospective studies, randomized trials and cancer registries provide conflicting data and do not support a generalized increase in NENs with the use of GLP-1RA. Some epidemiological studies have even shown survival benefits associated with GLP-1RA use. In addition, significant gaps in evidence remain, such as lack of data regarding certain tumor subtypes, long-term prospective studies with NENs as the clinical endpoint and uncertainty regarding patients with multiple endocrine neoplasia type 1. Hence, the initiation of GLP-1RA therapy in patient with predisposition to NENs where a contraindication does not exist, should be approached cautiously with careful monitoring for long-term adverse effects.<\/jats:p>","DOI":"10.1093\/ejendo\/lvag135","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:38:12Z","timestamp":1784979492000},"page":"R65-R72","source":"Crossref","is-referenced-by-count":0,"title":["Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms"],"prefix":"10.1093","volume":"195","author":[{"given":"Lakshmipriya Thandiyekkal","family":"Rajan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Sector of Endocrinology, Erasmus MC and Erasmus MC Cancer Center , 3015 GD Rotterdam ,","place":["The Netherlands"]},{"name":"Department of Endocrinology, Sanjay Gandhi Post Graduate Institute of Medical Sciences , Lucknow 226014 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-6209","authenticated-orcid":false,"given":"Johannes","family":"Hofland","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sector of Endocrinology, Erasmus MC and Erasmus MC Cancer Center , 3015 GD Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4045-4835","authenticated-orcid":false,"given":"Eskeatnaf","family":"Mulugeta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sector of Endocrinology, Erasmus MC and Erasmus MC Cancer Center , 3015 GD Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1463-5165","authenticated-orcid":false,"given":"Wouter W","family":"de Herder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sector of Endocrinology, Erasmus MC and Erasmus MC Cancer Center , 3015 GD Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"issue":"7","key":"2026093004225094100_lvag135-B1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/obr.12421","article-title":"The incretin system ABCs in obesity and diabetes\u2014novel therapeutic strategies for weight loss and beyond","volume":"17","author":"Jo\u00e3o","year":"2016","journal-title":"Obes Rev"},{"issue":"2","key":"2026093004225094100_lvag135-B2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2337\/dc09-1499","article-title":"Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits","volume":"33","author":"Drucker","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"2026093004225094100_lvag135-B3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2026093004225094100_lvag135-B4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/ndt\/gfaf193","article-title":"The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis","volume":"41","author":"Sasaki","year":"2026","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2026093004225094100_lvag135-B5","doi-asserted-by":"publisher","first-page":"zsae280","DOI":"10.1093\/sleep\/zsae280","article-title":"Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis","volume":"48","author":"Li","year":"2025","journal-title":"Sleep"},{"issue":"7","key":"2026093004225094100_lvag135-B6","doi-asserted-by":"publisher","first-page":"102214","DOI":"10.1016\/j.xcrm.2025.102214","article-title":"The expanding benefits of GLP-1 medicines","volume":"6","author":"Gonzalez-Rellan","year":"2025","journal-title":"Cell Rep Med"},{"issue":"7","key":"2026093004225094100_lvag135-B7","doi-asserted-by":"publisher","first-page":"R200","DOI":"10.1530\/EC-21-0130","article-title":"How glucagon-like peptide 1 receptor agonists work","volume":"10","author":"Andreasen","year":"2021","journal-title":"Endocr Connect"},{"key":"2026093004225094100_lvag135-B8"},{"issue":"4","key":"2026093004225094100_lvag135-B9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/thy.2023.0530","article-title":"Glucagon-like peptide-1 receptor agonists and thyroid cancer: a narrative review","volume":"34","author":"Espinosa De Ycaza","year":"2024","journal-title":"Thyroid"},{"issue":"4","key":"2026093004225094100_lvag135-B10","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"5","key":"2026093004225094100_lvag135-B11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting","volume":"48","author":"K\u00f6rner","year":"2007","journal-title":"J Nucl Med"},{"issue":"5","key":"2026093004225094100_lvag135-B12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","article-title":"Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting","volume":"30","author":"Reubi","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2026093004225094100_lvag135-B13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026093004225094100_lvag135-B14"},{"issue":"33","key":"2026093004225094100_lvag135-B15","doi-asserted-by":"publisher","first-page":"11529","DOI":"10.1074\/jbc.RA120.014368","article-title":"Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells","volume":"295","author":"Gray","year":"2020","journal-title":"J Biol Chem"},{"key":"2026093004225094100_lvag135-B16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fendo.2012.00158","article-title":"Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications","volume":"3","author":"K\u00f6rner","year":"2012","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026093004225094100_lvag135-B17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00428-025-04098-2","article-title":"GLP-1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades","volume":"486","author":"Watanabe","year":"2025","journal-title":"Virchows Arch"},{"issue":"1","key":"2026093004225094100_lvag135-B18","doi-asserted-by":"publisher","first-page":"e250051","DOI":"10.1530\/EO-25-0051","article-title":"Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies","volume":"5","author":"Ear","year":"2025","journal-title":"Endocr Oncol"},{"issue":"3","key":"2026093004225094100_lvag135-B19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/modpathol.2014.113","article-title":"Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas","volume":"28","author":"Waser","year":"2015","journal-title":"Mod Pathol"},{"issue":"4","key":"2026093004225094100_lvag135-B20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000330447","article-title":"Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy","volume":"94","author":"Waser","year":"2011","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2026093004225094100_lvag135-B21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon like peptide-1 receptor expression in the human thyroid gland","volume":"97","author":"Gier","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026093004225094100_lvag135-B22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(13)70049-4","article-title":"Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study","volume":"1","author":"Christ","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026093004225094100_lvag135-B23","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41598-017-18855-0","article-title":"Increased expression of GLP-1R in proliferating islets of Men1 mice is detectable by [68Ga]Ga-DO3A-VS-Cys40-Exendin-4\/PET","volume":"8","author":"Monazzam","year":"2018","journal-title":"Sci Rep"},{"issue":"2-3","key":"2026093004225094100_lvag135-B24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0014-5793(96)00895-2","article-title":"Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1","volume":"393","author":"Lamari","year":"1996","journal-title":"FEBS Lett"},{"issue":"6","key":"2026093004225094100_lvag135-B25","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4158\/EP.17.6.957","article-title":"Activation of G-protein-coupled receptors and thyroid malignant tumors: the jury is still out","volume":"17","author":"Gagel","year":"2011","journal-title":"Endocr Pract"},{"issue":"1","key":"2026093004225094100_lvag135-B26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/jcpt.13259","article-title":"Glucagon-like peptide-1 analogues and thyroid cancer: an analysis of cases reported in the European pharmacovigilance database","volume":"46","author":"Mali","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"2026093004225094100_lvag135-B27","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 Receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"issue":"5","key":"2026093004225094100_lvag135-B28","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.2337\/dc22-2300","article-title":"Comment on Bezin et al. GLP-1 receptor agonists and the risk of thyroid cancer. diabetes care 2023;46:384-390","volume":"46","author":"Goldenberg","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"2026093004225094100_lvag135-B29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/dom.15382","article-title":"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026093004225094100_lvag135-B30","doi-asserted-by":"publisher","first-page":"925377","DOI":"10.3389\/fphar.2022.925377","article-title":"GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"2026093004225094100_lvag135-B31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/thy.2024.0387","article-title":"Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study","volume":"35","author":"Baxter","year":"2025","journal-title":"Thyroid"},{"issue":"10","key":"2026093004225094100_lvag135-B32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1089\/thy.2019.0591","article-title":"Medullary thyroid carcinoma surveillance study: a case-series registry","volume":"30","author":"Hale","year":"2020","journal-title":"Thyroid"},{"key":"2026093004225094100_lvag135-B33","author":"Medullary Thyroid Carcinoma (MTC) Registry Consortium | American Thyroid Association"},{"key":"2026093004225094100_lvag135-B34"},{"key":"2026093004225094100_lvag135-B35","doi-asserted-by":"publisher","first-page":"927859","DOI":"10.3389\/fendo.2022.927859","article-title":"Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials","volume":"13","author":"Hu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026093004225094100_lvag135-B36","doi-asserted-by":"publisher","first-page":"e2080","DOI":"10.1210\/clinem\/dgae722","article-title":"Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists","volume":"110","author":"Kelly","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026093004225094100_lvag135-B37","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats","volume":"48","author":"Xu","year":"1999","journal-title":"Diabetes"},{"issue":"6","key":"2026093004225094100_lvag135-B38","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1152\/ajpendo.00007.2004","article-title":"Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells","volume":"286","author":"List","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026093004225094100_lvag135-B39","doi-asserted-by":"publisher","first-page":"108943","DOI":"10.1016\/j.surg.2024.09.052","article-title":"GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors","volume":"179","author":"Shilyansky","year":"2025","journal-title":"Surgery"},{"issue":"7","key":"2026093004225094100_lvag135-B40","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","volume":"62","author":"Butler","year":"2013","journal-title":"Diabetes"},{"issue":"7","key":"2026093004225094100_lvag135-B41","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/dom.12257","article-title":"Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies","volume":"16","author":"Bonner-Weir","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2026093004225094100_lvag135-B42","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"issue":"5","key":"2026093004225094100_lvag135-B43","doi-asserted-by":"publisher","first-page":"F77","DOI":"10.1530\/ERC-12-0111","article-title":"GLP1 and cancer: friend or foe?","volume":"19","author":"Vangoitsenhoven","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"2026093004225094100_lvag135-B44"},{"issue":"1","key":"2026093004225094100_lvag135-B45","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/s41598-019-38956-2","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis","volume":"9","author":"Pinto","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"2026093004225094100_lvag135-B46","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3390\/cancers17091593","article-title":"Survival benefits of GLP-1 receptor agonists in patients with neuroendocrine neoplasms: a large-scale propensity-matched cohort study","volume":"17","author":"Fawzy","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026093004225094100_lvag135-B47","author":"Hong"},{"issue":"10","key":"2026093004225094100_lvag135-B48","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1210\/jc.2017-00372","article-title":"Long-term natural course of small nonfunctional pancreatic neuroendocrine tumors in MEN1-results from the Dutch MEN1 study group","volume":"102","author":"Pieterman","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026093004225094100_lvag135-B49","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/SLA.0000000000002183","article-title":"Management of MEN1 related nonfunctioning pancreatic NETs: a shifting paradigm: results from the DutchMEN1 study group","volume":"267","author":"Nell","year":"2018","journal-title":"Ann Surg"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag135\/70442770\/lvag135.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/3\/R65\/70442770\/lvag135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/3\/R65\/70442770\/lvag135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:22:57Z","timestamp":1790756577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/195\/3\/R65\/8748881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag135","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,1]]}}}